Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063351 | 0.98 | KMT2A (1.00) | KMT2AMEN1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL8564336 | 0.93 | MEN1 (0.83) | KMT2AMEN1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL9281354 | 0.86 | CYP3A4 (0.73) | KMT2AMEN1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL17007472 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2TSHRMAPT | |
| SCHEMBL6568319 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2TSHRMAPT | |
| SCHEMBL20021983 | 0.85 | KMT2A (0.71) | KMT2AMEN1SMN1; SMN2TSHRMAPT | |
| SCHEMBL2960623 | 0.85 | MEN1 (0.71) | KMT2AMEN1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL4389694 | 0.84 | MEN1 (0.74) | KMT2AMEN1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL14919477 | 0.82 | MEN1 (0.68) | KMT2AMEN1SMN1; SMN2TSHRMAPT | |
| SCHEMBL2952847 | 0.82 | MAPT (0.71) | KMT2AMEN1SMN1; SMN2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | KMT2A 4002/4885MEN1 4593/4885SMN1; SMN2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.